Table 2.
Distribution of biomarkers in brain metastasis (BrM) and NBrWoM patients in both Luminal and non-Luminal groups.
| Patients (N = 208) | ||||
|---|---|---|---|---|
| Biomarker | Luminal group (N = 141) |
Non-Luminal group (N = 67) |
||
| BrM | NBrWoMa | BrM | NBrWoMa | |
| N (%) | N (%) | N (%) | N (%) | |
| FN14+b | 7/13 (53.8) | 13/125 (10.4) | 12/38 (31.6) | 3/27 (11.1) |
| Fisher’s exact test (p = 0.0005) | Fisher’s exact test (p = 0.07) | |||
| GRP94+c | 10/13 (76.9) | 56/126 (44.4) | 22/38 (57.9) | 11/28 (39.3) |
| Fisher’s exact test (p = 0.04) | Fisher’s exact test (p = 0.21) | |||
aThis category encompasses those patients “without metastases” and those with “non-brain distant metastases” [bone, lung, liver, and non-regional lymph node metastases; in this category, five patients were previously excluded because they only had skin metastasis (n = 2), pleural metastasis (n = 2), or meningeal metastasis (n = 1)].
bFN14 biomarker was assessed in 138 patients belonging to the Luminal group (this was not possible in 3 of them) and in 65 from the non-Luminal group (this was not possible in 2 of them).
cGRP94 biomarker was assessed in 139 patients belonging to the Luminal group (this was not possible in 2 of them) and in 66 from the non-Luminal one (this was not possible for 1 of them).
Differences shown in number of patients (N) in each group are due to patients whose biomarkers were not available.